Journal of the Formosan Medical Association最新文献

{"title":"Reply to comments on \"A comparative analysis of MMR immunohistochemistry panels: Evaluating the utility of four-protein versus two-protein panels in endometrial cancer patients\".","authors":"Hao Lin, Yu-Sheng Huang","doi":"10.1016/j.jfma.2025.03.012","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.012","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to comments on \"the association of temporalis muscle thickness with post-stroke dysphagia based on swallowing kinematic analysis\".","authors":"Kuan-Yu Chen, Meng-Ting Lin","doi":"10.1016/j.jfma.2025.03.011","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.011","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-operative oropharyngeal rehabilitation suppress oxidative stress and inflammation in obstructive sleep apnea patients with transoral robotic surgery.","authors":"Yi-Ju Lai, Chung-Yi Li, Kun-Ling Tsai, Ching-Hsia Hung, Cheng-Yu Lin","doi":"10.1016/j.jfma.2025.03.004","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.004","url":null,"abstract":"<p><strong>Purpose: </strong>To demonstrate the effects of postoperative oropharyngeal rehabilitation on inflammatory mediators and antioxidant capacity in adults with obstructive sleep apnea.</p><p><strong>Methods: </strong>This quasi-experimental study enrolled participants without blinding between January 2020 and December 2022. Patients with obstructive sleep apnea were divided into a conservative treatment group (n = 17), surgery group (n = 23), or surgery combined with oropharyngeal rehabilitation (surgery + rehabilitation) group (n = 19). Polysomnography data and the concentration of inflammatory mediators and antioxidant capacity were determined at baseline, after 6 weeks of treatment, and after 18 weeks of treatment.</p><p><strong>Results: </strong>Posttreatment percent changes in the apnea-hypopnea index in rapid eye movement sleep were positively correlated with that of IL-6 (0.641, 95% CI: 0.598 to 0.685; P < 0.001). Compared with the patients in the control group, those in the surgery + rehabilitation group had significantly reduced posttreatment percent changes in IL-6 (-77.273, 95% CI: -144.580 to -9.966; P = 0.024). In addition, the concentrations of IL-6 (-3.423, 95% CI: -6.638 to -0.207; P = 0.037) and matrix metallopeptidase-9 (-20.517, 95% CI: -40.584 to -0.450; P = 0.045) significantly decreased in the surgery + rehabilitation group. The total antioxidant capacity significantly improved in the surgery + rehabilitation group compared with in the surgery-only group (0.034, 95% CI: 0.005 to 0.063; P = 0.020).</p><p><strong>Conclusion: </strong>The results reveal that postoperative oropharyngeal rehabilitation can reduce the serum levels of inflammatory mediators and increase antioxidant capacity. The combined treatment is more effective than surgery-only or conservative treatment.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Language and motor plasticity in toddlerhood and early preschool as predictors of intelligence in late preschool.","authors":"Chang Chen, Yu-Ju Lin, Hsin-Hui Lu, Jao-Shwann Liang, Huey-Ling Chiang","doi":"10.1016/j.jfma.2025.03.005","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.005","url":null,"abstract":"<p><strong>Background: </strong>Early language and motor development may influence cognitive function in a cascading manner later in life. This study aimed to explore the impact of language and motor plasticity during toddlerhood and early preschool years on intelligence in late preschool, with an additional consideration of the influence of ASD and ADHD diagnoses.</p><p><strong>Methods: </strong>We retrospectively collected medical chart from 423 children aged 2-5 years (316 boys and 107 girls; mean age at Time 1: 3.49 ± 0.98 years), who participated in an early intervention program at a medical center in Northern Taiwan. Language and motor development along with demographic information were assessed during the initial evaluation (Time 1). These assessments were repeated, and intelligence was measured at the follow-up (Time 2). A generalized linear model was used for the data analysis.</p><p><strong>Results: </strong>Receptive language developmental change was the strongest predictor of lower intelligence quotient (IQ) scores, followed by gross, expressive language, and fine motor developmental changes (all p < 0.01). Children with catch-up receptive or expressive language or gross or fine motor development had better IQ outcomes than those with persistent delay (all p < 0.001). There were no ASD-by-developmental type or ADHD-by-developmental type interactions predicting IQ.</p><p><strong>Conclusions: </strong>Better plasticity in language and motor abilities during toddlerhood and early pre-school years was associated with better intelligence in the late pre-school years. The importance of early and effective interventions for language and motor development has been highlighted.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study\".","authors":"Fu Lou, Xiaohong Fan","doi":"10.1016/j.jfma.2025.03.007","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.007","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyrotinib combined with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer after the progression of trastuzumab therapy.","authors":"Xiangping Mei, Yue Hu, Huijie Liu, Hongge Wu, Linka Xie, Jie Xiong, Yuehua Wang, Jing Yao","doi":"10.1016/j.jfma.2025.03.003","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.003","url":null,"abstract":"<p><strong>Introduction: </strong>Retrospective studies have shown that the continuation use of trastuzumab in HER2 positive metastatic breast cancer patients who progressed during treatment with trastuzumab still may have clinical benefits. However, the optimal strategy was still unknown. We conducted this study aiming to explore the efficacy and safety of pyrotinib plus chemotherapy with or without trastuzumab in HER2 positive MBC patients who progressed after previous trastuzumab treatment.</p><p><strong>Methods: </strong>This was a real-world retrospective study that enrolled HER2 positive MBC patients previously treated with trastuzumab. Patients were divided into control group (pyrotinib combined with chemotherapy) and combined group (trastuzumab combined with pyrotinib and chemotherapy). The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective remission rate (ORR), disease control rate (DCR) and safety.</p><p><strong>Results: </strong>A total of 101 patients were included in the analysis with median follow-up time of 25.5 months (95%CI, 22.5-33.0). The median PFS was 19.1 months (95%CI 10.5-NA, P = 0.039) in combined group and 11.5 months (95%CI 8.1-15.1) in control group. The ORR was 55.6% in the combined group compared with 43.0% in the control group(P = 0.299), and the DCR was 100% compared with 87.7% respectively(P = 0.028). The most common grade 3 or 4 adverse events were diarrhea [7(25.0%)], neutropenia [5(14.3%)] and leukopenia [4(11.4%)] in combined group and diarrhea [3(5.0%)], neutropenia [3(5.0%)] and leukopenia [3(5.0%)] in control group.</p><p><strong>Conclusions: </strong>Trastuzumab combined with pyrotinib and chemotherapy showed clinical benefits and acceptable tolerance in HER2-positive MBC patients previously treated with trastuzumab. Thus, these combination regimens may be potential options for such patients.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of prognosis and immune response in lung adenocarcinoma by peroxisome related-lncRNA.","authors":"Yabo Lou, Honggang Wang, Qunzhi Wang, Xin Shi","doi":"10.1016/j.jfma.2025.03.008","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.008","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) represents the primary tissue subtype of lung cancer, characterized by a significant mortality rate and unfavorable prognosis. Long non-coding RNAs (lncRNAs) serve as critical functional units in the initiation and progression of tumors. Peroxisomes, now recognized as vital organelles in tumor immune metabolism, have garnered considerable attention in recent research. Some LncRNAs regulate peroxisome protein conformation through the mechanism of RNA molecular chaperones to maintain its normal function. This study aims to investigate the role of peroxisome-related lncRNA signatures in predicting clinical outcomes and immunotherapy efficacy, as well as their correlation with drug sensitivity.</p><p><strong>Methods: </strong>The genomic and clinical information stemmed from the Cancer Genome Atlas (TCGA) database, while the peroxisome-related genes came from relevant studies. We developed prognostic features through co-expression analysis, Cox regression analysis, and LASSO analysis. Then we classified patients into high-risk and low-risk cohorts and performed extensive model validations to assess the prognostic significance of the signature. We used RT-qPCR to detect the expression of six peroxisome-associated lncRNAs in lung adenocarcinoma cells. Following this, we analyzed immune-related functions and tumor mutation burden (TMB). Lastly, we identified potential drugs and evaluated the drug sensitivity for LUAD.</p><p><strong>Results: </strong>We identified six peroxisome-related lncRNAs that serve as prognostic biomarkers. Our analysis revealed that high-risk patients exhibited decreased survival rates and increased mortality. Independent prognostic evaluations, receiver operating characteristic (ROC) curves, and bar charts demonstrated that these peroxisome-related lncRNAs can effectively predict patient outcomes. RT-qPCR results also indicated that these peroxisomes showed significant differences in mRNA expression in lung normal and lung adenocarcinoma cells. Moreover, in high-risk individuals, we observed reduced immune cell infiltration, inhibited immune functions, and an elevated tumor mutational burden (TMB). Consequently, high-risk patients faced a higher likelihood of immune evasion, resulting in diminished effectiveness of immunotherapy.</p><p><strong>Conclusion: </strong>In conclusion, the six lncRNAs linked to peroxisomes can reliably forecast the prognosis of LUAD patients and may offer novel perspectives for clinical applications and immunotherapy.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Ovarian stimulation response and fertility outcomes in patients with breast cancer across different stages, grades, and hormone receptor status for fertility preservation\".","authors":"Huabin Wang, Xiaoyan Ma","doi":"10.1016/j.jfma.2025.03.001","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.001","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of continuous versus on-demand proton pump inhibitor therapy in symptom control of patients with Barrett's esophagus.","authors":"Sung-Shuo Kao, Deng-Chyan Wu, Seng-Kee Chuah, John Y Kao, Wei-Chen Tai, Chang-Bih Shie, I-Ting Wu, Wen-Chih Chen, Feng-Woei Tsay, Yan-Hua Chen, Ping-I Hsu","doi":"10.1016/j.jfma.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.006","url":null,"abstract":"<p><strong>Background: </strong>Whether continuous proton pump inhibitor (PPI) therapy is superior to on-demand therapy for symptom control of Barrett's esophagus patients is unclear. The study aimed to compare the efficacies of the symptom control and the frequency of co-existent erosive esophagitis in patients with Barrett's esophagus by either continuous or on-demand PPI therapy.</p><p><strong>Methods: </strong>We randomly assigned (1:1) consecutive adult patients with symptomatic Barrett's esophagus to receive on-demand or continuous esomeprazole (40 mg q.d.) therapy for 40 weeks following an initial treatment with esomeprazole 40 mg daily for 8 weeks. A follow-up endoscopy was conducted at week 48. The primary outcome was total number of symptomatic days. The secondary outcome was the frequency of co-existent erosive esophagitis at week 48.</p><p><strong>Results: </strong>From February 2010 to December 2022, we randomly assigned 235 eligible patients to receive either on-demand (n = 119) or continuous (n = 116) esomeprazole therapy. The on-demand and continuous groups did not signicantly differ in symptom scores at each follow-up time point. Two treatment groups had a comparable total number of symptom days (27.7 ± 41.5 vs 24.3 ± 47.7; P = 0.570) but the on-demand group took fewer esomeprazole tablets than the continuous group (230.6 ± 96.5 vs 330.0 ± 15.6; P < 0.001). At week 48, the on-demand and continuous groups had comparable frequencies of erosive esophagitis (10.6% vs 6.7%).</p><p><strong>Conclusion: </strong>On-demand PPI therapy reduces the total amount of PPI used while achieving similar symptom relief compared to continuous PPI therapy in patients with Barrett's esophagus.</p>","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporalis muscle thickness and post-stroke dysphagia.","authors":"Ziye Li","doi":"10.1016/j.jfma.2025.03.002","DOIUrl":"https://doi.org/10.1016/j.jfma.2025.03.002","url":null,"abstract":"","PeriodicalId":17305,"journal":{"name":"Journal of the Formosan Medical Association","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}